ABSTRACT
Cancer-related pain is a common and debilitating condition that can significantly affect the quality of life of patients. Opioids, NSAIDs, and antidepressants are among the first-line therapies, but their efficacy is limited or their use can be restricted due to serious side effects. Neuromodulation and lesioning techniques have also proven to be a valuable instrument for managing refractory pain. For patients who have exhausted all standard treatment options, hypophysectomy may be an effective alternative treatment. We conducted a comprehensive systematic review of the available literature on PubMed and Scielo databases on using hypophysectomy to treat refractory cancer-related pain. Data extraction from included studies included study design, treatment model, number of treated patients, sex, age, Karnofsky Performance Status (KPS) score, primary cancer site, lead time from diagnosis to treatment, alcohol injection volume, treatment data, and clinical outcomes. Statistical analysis was reported using counts (N, %) and means (range). The study included data from 735 patients from 24 papers treated with hypophysectomy for refractory cancer-related pain. 329 cancer-related pain patients were treated with NALP, 216 with TSS, 66 with RF, 55 with Y90 brachytherapy, 51 with Gamma Knife radiosurgery (GK), and 18 with cryoablation. The median age was 58.5 years. The average follow-up time was 8.97 months. Good pain relief was observed in 557 out of 735 patients, with complete pain relief in 108 out of 268 patients. Pain improvement onset was observed 24 h after TSS, a few days after NALP or cryoablation, and a few days to 4 weeks after GK. Complications varied among treatment modalities, with diabetes insipidus (DI) being the most common complication. Although mostly forgotten in modern neurosurgical practice, hypophysectomy is an attractive option for treating refractory cancer-related pain after failure of traditional therapies. Radiosurgery is a promising treatment modality due to its high success rate and reduced risk of complications.
Subject(s)
Cancer Pain , Hypophysectomy , Humans , Cancer Pain/surgery , Pain Management , Pain, Intractable/surgery , Pain, Intractable/etiology , Quality of Life , Radiosurgery/methods , Treatment OutcomeABSTRACT
Previously, we reported that the administration of a mixture of Humulus japonicus (MH) increased the longitudinal bone growth rate in Sprague Dawley rats. In this study, we investigated the effects of the dietary administration of MH on longitudinal bone growth in growth hormone (GH)-deficient hypophysectomized male and female rats to determine whether the effect of MH was similar to that of GH. We measured the nose-to-anus and nose-to-tail length gain, femur and tibia lengths, growth plate zones, and expression of insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) after the dietary administration of MH or the injection of GH into hypophysectomized rats for 4 weeks. Results demonstrated that the dietary administration of MH had no effect on longitudinal bone growth, whereas the injection of GH increased the nose-to-tail length gain and femur and tibia lengths in hypophysectomized rats. In addition, MH did not affect the growth plate, bone mineralization, and expression of IGF-1 and IGFBP-3. These findings indicate that MH does not exert a GH-like effect and that the effects of MH and GH on longitudinal bone growth involve different pathways.
Subject(s)
Humulus , Animals , Bone Development , Female , Growth Hormone , Hypophysectomy , Insulin-Like Growth Factor I/genetics , Male , Rats , Rats, Sprague-DawleyABSTRACT
BACKGROUND: Acromegaly is so rare that its natural history, including incidence, risk of cancers, and mortality rates, remains elusive. This natural study utilized a nationwide database to provide a better understanding of acromegaly's disease course. METHODS: A cohort of 1,195 acromegaly patients were identified and followed-up from 1997 to 2013. Incidence, operation, and re-operation rates were calculated. Excessive mortality and cancer risk related to acromegaly were estimated by standardized mortality ratio (SMR) and standardized incidence ratio (SIR). RESULTS: The incidence was 2.78 per million-person-years, with little gender predominance (female vs. male, 49.5 vs. 50.5%, respectively). There was female predominance only among 50 and 60 year-olds (incidence rate ratio: 1.37 and 1.43, p < 0.001 and p = 0.002). Among them, 673 (56.3%) had hypophysectomy surgery, and the young-onset (<40 years) patients had more re-operations (15.5%, p = 0.01). The overall mortality rate was 22.3 per 1,000 person-years, with a median survival of 4.67 years (with no gender differences, p = 0.38). The overall SMR of acromegaly patients was 1.41, and the onset-age-specific SMRs of the early- and middle-onset patients were higher than for those with late-onset. There were 87 newly diagnosed cancers in the cohort, with an incidence rate of 10.6 per 1,000 person-years (median 5.4 years). The overall SIR of cancers was 1.91, and there were no differences among gender, onset-age, and disease duration (all SIR >1, approximately 2). CONCLUSION: Acromegaly is associated with an excessive risk of mortality and two-fold higher risk of cancers. Patients with acromegaly should be managed appropriately after the diagnosis.
Subject(s)
Acromegaly/epidemiology , Acromegaly/surgery , Hypophysectomy/statistics & numerical data , Neoplasms/epidemiology , Reoperation/statistics & numerical data , Adolescent , Adult , Age of Onset , Aged , Child , Child, Preschool , Comorbidity , Female , Follow-Up Studies , Humans , Incidence , Infant , Male , Middle Aged , Mortality , National Health Programs/statistics & numerical data , Retrospective Studies , Risk , Survival Analysis , Taiwan/epidemiology , Young AdultABSTRACT
CONTEXT: The improved remission and complication rates of current transsphenoidal surgery warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in the treatment algorithm of prolactinomas. OBJECTIVE: To compare clinical outcomes after dopamine agonist withdrawal and transsphenoidal surgery in prolactinoma patients. METHODS: Eight databases were searched up to July 13, 2018. Primary outcome was disease remission after drug withdrawal or surgery. Secondary outcomes were biochemical control and side effects during dopamine agonist treatment and postoperative complications. Fixed- or random-effects meta-analysis was performed to estimate pooled proportions. Robustness of results was assessed by sensitivity analyses. RESULTS: A total of 1469 articles were screened: 55 (10 low risk of bias) on medical treatment (n = 3564 patients) and 25 (12 low risk of bias) on transsphenoidal surgery (n = 1836 patients). Long-term disease remission after dopamine agonist withdrawal was 34% (95% confidence interval [CI], 26-46) and 67% (95% CI, 60-74) after surgery. Subgroup analysis of microprolactinomas showed 36% (95% CI, 21-52) disease remission after dopamine agonist withdrawal, and 83% (95% CI, 76-90) after surgery. Biochemical control was achieved in 81% (95% CI, 75-87) of patients during dopamine agonists with side effects in 26% (95% CI, 13-41). Transsphenoidal surgery resulted in 0% mortality, 2% (95% CI, 0-5) permanent diabetes insipidus, and 3% (95% CI, 2-5) cerebrospinal fluid leakage. Multiple sensitivity analyses yielded similar results. CONCLUSIONS: In the majority of prolactinoma patients, disease remission can be achieved through surgery, with low risks of long-term surgical complications, and disease remission is less often achieved with dopamine agonists.
Subject(s)
Critical Pathways/standards , Dopamine Agonists/therapeutic use , Hypophysectomy/methods , Microsurgery/methods , Pituitary Neoplasms/therapy , Prolactinoma/therapy , Dopamine Agonists/pharmacology , Dopamine Agonists/standards , Female , Humans , Hypophysectomy/adverse effects , Hypophysectomy/standards , Microsurgery/adverse effects , Microsurgery/standards , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Pituitary Gland/pathology , Pituitary Gland/surgery , Pituitary Neoplasms/pathology , Practice Guidelines as Topic , Prolactin/metabolism , Prolactinoma/pathology , Remission Induction/methods , Retrospective Studies , Treatment OutcomeABSTRACT
In patients undergoing endoscopic transsphenoidal hypophysectomy, the nasal mucosa is often infiltrated with local anesthetic solutions that contain epinephrine to aid hemostasis. This may, however, result in hemodynamic changes, especially hypotension. We characterized the cardiovascular changes using a LiDCOrapid monitor in 13 patients after the infiltration of 4% articaine containing 1:200,000 epinephrine. Nine (69%) had a >20% decrease in mean arterial pressure at a median time of 116 seconds after the infiltration of articaine with epinephrine. Analysis of the cardiac output data revealed that this was caused by a sustained reduction in systemic vascular resistance. The arterial blood pressure normalized over a period of 60 to 90 seconds secondary to increases in stroke volume and heart rate producing an elevation in cardiac output. Transient hypotension following the infiltration of epinephrine-containing local anesthetics may be caused by epinephrine stimulation of ß2-adrenoceptors producing vasodilation.
Subject(s)
Anesthesia, Local/adverse effects , Epinephrine/adverse effects , Hypophysectomy/methods , Hypotension/chemically induced , Hypotension/physiopathology , Nasal Cavity/surgery , Vasoconstrictor Agents/adverse effects , Adult , Aged , Anesthetics, Local/administration & dosage , Anesthetics, Local/adverse effects , Blood Pressure/drug effects , Carticaine/administration & dosage , Carticaine/adverse effects , Epinephrine/administration & dosage , Female , Heart Rate/drug effects , Humans , Hypophysectomy/adverse effects , Male , Middle Aged , Nasal Mucosa , Prospective Studies , Stroke Volume/drug effects , Vascular Resistance/drug effects , Vasoconstrictor Agents/administration & dosageABSTRACT
The transsphenoidal approach has been utilized in intrasellar craniopharyngioma surgeries. However, the advent of endoscopic extended transsphenoidal approach (EETSA) has expanded its indication to suprasellar craniopharyngiomas. We compared the indication and limitations of EETSA to those of unilateral basal interhemispheric approach (UBIHA), which presents similar indications for surgery. We analyzed 30 patients with tumors located below the foramen of Monro and the lateral boundary extending slightly beyond the internal carotid artery (UBIHA: N = 18; EETSA: N = 12). Postoperative magnetic resonance imaging (MRI) revealed gross total resection in 10 patients in the EETSA group (83.3%) and 12 in the UBIHA group (66.7%). Postoperative MRI in the EETSA group revealed residual tumor at the cavernous sinus in one patient, at the prepontine in one; in the UBIHA group, residual tumors were located in the retrochiasmatic area in two patients, infundibulum-hypothalamus in one, on the stalk in one, and in the intrasellar region in two. No intergroup differences were observed in the preservation of pituitary function and postoperative improvement of visual function. The extent of resection was better with EETSA than with UBIHA. EETSA is considered the first-line therapy because the distance between the optic chiasm and the superior border of the pituitary is large; the lateral extension does not go beyond the internal carotid artery; and the tumor does not extend inferiorly beyond the posterior clinoid process. However, in patients showing poorly developed sphenoid sinuses or pituitary stalks anterior to the tumor, surgery is difficult regardless of the selection criteria.
Subject(s)
Craniopharyngioma/surgery , Hypophysectomy/methods , Neuroendoscopy/methods , Pituitary Neoplasms/surgery , Craniopharyngioma/classification , Craniopharyngioma/diagnosis , Humans , Hypothalamus/surgery , Magnetic Resonance Imaging , Neoplasm, Residual/diagnosis , Pituitary Function Tests , Pituitary Neoplasms/classification , Pituitary Neoplasms/diagnosis , Postoperative Complications/diagnosis , Sphenoid Sinus/surgeryABSTRACT
BACKGROUND: Prognosis in childhood cranio-pharyngioma, is frequently impaired due to sequelae. Radical surgery was the treatment of choice for decades. Even at experienced facilities radical surgery can result in hypothalamic disorders such as severe obesity. OBJECTIVE: We analyzed, whether treatment strategies for childhood craniopharyngioma patients recruited in GPOH studies have changed during the last 12 years. MATERIALS AND METHODS: We compared the grade of pre-surgical hypothalamic involvement, treatment, degree of resection and grade of surgical hypothalamic lesions between patients recruited in KRANIOPHARYNGEOM 2000 (n=120; 2001-2007) and KRANIOPHARYNGEOM 2007 (n=106; 2007-2012). RESULTS: The grade of initial hypothalamic involvement was similar in patients treated 2001-2007 and 2007-2012. The realized treatment was more radical (p=0.01) in patients recruited 2001-2007 (38%) when compared with patients treated 2007-2012 (18%). In patients with pre-surgical involvement of anterior/posterior hypothalamic areas, the rate of hypothalamus-sparing operations resulting in no (further) hypothalamic lesions was higher (p=0.005) in patients treated 2007-2012 (35%) in comparison with the 2001-2007 cohort (13%). Event-free-survival rates were similar in both cohorts. CONCLUSIONS: A trend towards less radical surgical approaches is observed, which was accompanied by a reduced rate of severe hypothalamic lesions. Radical surgery is not an appropriate treatment strategy in patients with hypothalamic involvement. Despite previous recommendations to centralize treatment at specialized centers, a trend towards further decentralization was seen.
Subject(s)
Craniopharyngioma/pathology , Craniopharyngioma/surgery , Hypophysectomy/methods , Hypophysectomy/trends , Hypothalamus/surgery , Pituitary Neoplasms/pathology , Pituitary Neoplasms/surgery , Adolescent , Austria , Belgium , Body Mass Index , Child , Child, Preschool , Clinical Trials as Topic , Cohort Studies , Craniopharyngioma/mortality , Disease-Free Survival , Female , Germany , Humans , Hypothalamic Diseases/etiology , Hypothalamic Diseases/mortality , Hypothalamus/pathology , Infant , Magnetic Resonance Imaging , Male , Neoplasm Grading , Neoplasm Invasiveness/pathology , Obesity/etiology , Obesity/mortality , Pituitary Neoplasms/mortality , Postoperative Complications/etiology , Postoperative Complications/mortality , Prognosis , Quality of Life , SwitzerlandABSTRACT
Cushing disease is caused by excessive adrenocorticotropic hormone (ACTH) production by the pituitary adenoma. Transsphenoidal surgery is its first-line treatment. The incidence of Cushing disease in children and adolescents is so rare that long-term prognoses have yet to be made in most cases. We followed-up on a 16-year-old male Cushing disease patient who presented with rapid weight gain and growth retardation. The laboratory findings showed increased 24-hour urine free cortisol and lack of overnight cortisol suppression by low-dose dexamethasone test. The serum cortisol and 24-hour urine free cortisol, by high-dose dexamethasone test, also showed a lack of suppression, and a bilateral inferior petrosal sinus sampling suggested lateralization of ACTH secretion from the right-side pituitary gland. However, after a right hemihypophysectomy by the transsphenoidal approach, the 24-hour urine free cortisol levels were persistently high. Thus the patient underwent a total hypophysectomy, since which time he has been treated with hydrocortisone, levothyroxine, recombinant human growth hormone, and testosterone enanthate. Intravenous bisphosphonate for osteoporosis had been administered for three years. At his current age of 26 years, his final height had attained the target level range; his bone mineral density was normal, and his pubic hair was Tanner stage 4. This report describes the long-term treatment course of a Cushing disease patient according to growth profile, pubertal status, and responses to hormone replacement therapy. The clinical results serve to emphasize the importance of growth optimization, puberty, and bone health in the treatment management of Cushing disease patients who have undergone transsphenoidal surgery.
Subject(s)
Adolescent , Child , Humans , Male , Adrenocorticotropic Hormone , Bone Density , Dexamethasone , Follow-Up Studies , Hair , Hormone Replacement Therapy , Human Growth Hormone , Hydrocortisone , Hypophysectomy , Hypopituitarism , Incidence , Osteoporosis , Petrosal Sinus Sampling , Pituitary ACTH Hypersecretion , Pituitary Gland , Pituitary Neoplasms , Prognosis , Puberty , Testosterone , Thyroxine , Weight GainABSTRACT
Fifteen years ago orexins were identified as central regulators of energy homeostasis. Since then, that concept has evolved considerably and orexins are currently considered, besides orexigenic neuropeptides, key modulators of sleep-wake cycle and neuroendocrine function. Little is known, however, about the effect of the neuroendocrine milieu on orexins' effects on energy balance. We therefore investigated whether hypothalamic-pituitary axes have a role in the central orexigenic action of orexin A (OX-A) by centrally injecting hypophysectomized, adrenalectomized, gonadectomized (male and female), hypothyroid, and GH-deficient dwarf rats with OX-A. Our data showed that the orexigenic effect of OX-A is fully maintained in adrenalectomized and gonadectomized (females and males) rats, slightly reduced in hypothyroid rats, and totally abolished in hypophysectomized and dwarf rats when compared with their respective vehicle-treated controls. Of note, loss of the OX-A effect on feeding was associated with a blunted OX-A-induced increase in the expression of either neuropeptide Y or its putative regulator, the transcription factor cAMP response-element binding protein, as well as its phosphorylated form, in the arcuate nucleus of the hypothalamus of hypophysectomized and dwarf rats. Overall, this evidence suggests that the orexigenic action of OX-A depends on an intact GH axis and that this neuroendocrine feedback loop may be of interest in the understanding of orexins action on energy balance and GH deficiency.
Subject(s)
Appetite Regulation , Growth Hormone/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Neurons/metabolism , Neuropeptides/metabolism , Pituitary Gland/metabolism , Receptors, Somatotropin/metabolism , Adrenalectomy/adverse effects , Animals , Castration/adverse effects , Cyclic AMP Response Element-Binding Protein/biosynthesis , Cyclic AMP Response Element-Binding Protein/metabolism , Dwarfism, Pituitary/metabolism , Dwarfism, Pituitary/physiopathology , Feeding Behavior , Female , Hypophysectomy/adverse effects , Hypothalamus/metabolism , Hypothyroidism/metabolism , Hypothyroidism/physiopathology , Injections, Intraventricular , Intracellular Signaling Peptides and Proteins/administration & dosage , Male , Neuropeptide Y/biosynthesis , Neuropeptide Y/metabolism , Neuropeptides/administration & dosage , Orexins , Rats , Rats, Inbred Lew , Rats, Sprague-DawleySubject(s)
Acromegaly/diagnosis , Acromegaly/therapy , Acromegaly/epidemiology , Acromegaly/etiology , Adenoma/drug therapy , Adenoma/epidemiology , Adenoma/metabolism , Adenoma/radiotherapy , Adenoma/surgery , Algorithms , Combined Modality Therapy , Comorbidity , Cranial Irradiation/methods , Dopamine Agonists/administration & dosage , Dopamine Agonists/adverse effects , Dopamine Agonists/therapeutic use , Glucose Tolerance Test , Growth Hormone-Secreting Pituitary Adenoma/drug therapy , Growth Hormone-Secreting Pituitary Adenoma/epidemiology , Growth Hormone-Secreting Pituitary Adenoma/metabolism , Growth Hormone-Secreting Pituitary Adenoma/radiotherapy , Growth Hormone-Secreting Pituitary Adenoma/surgery , Human Growth Hormone/administration & dosage , Human Growth Hormone/adverse effects , Human Growth Hormone/analogs & derivatives , Human Growth Hormone/blood , Human Growth Hormone/metabolism , Human Growth Hormone/therapeutic use , Humans , Hypophysectomy/methods , Insulin-Like Growth Factor I/metabolism , Magnetic Resonance Imaging , Neoadjuvant Therapy , Perioperative Care , Phenotype , Pituitary Neoplasms/drug therapy , Pituitary Neoplasms/epidemiology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/radiotherapy , Pituitary Neoplasms/surgery , Somatostatin/administration & dosage , Somatostatin/adverse effects , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Symptom AssessmentABSTRACT
A peptide pheromone of the red-bellied male newt, sodefrin was tested for its ability to increase intracellular concentrations of Ca(2+) ([Ca(2+)]i) in the dissociated vomeronasal (VN) cells of females by means of calcium imaging system. The pheromone elicited a marked elevation of [Ca(2+)]i in a small population of VN cells from sexually developed females. The population of cells exhibiting sodefrin-induced elevation of [Ca(2+)]i increased concentration-dependently. A pheromone of a different species was ineffective in this respect. The VN cells from non-reproductive females or from reproductive males scarcely responded to sodefrin in terms of elevating [Ca(2+)]i. In the cells from hypophysectomized and ovariectomized females, the sodefrin-inducible increase of [Ca(2+)]i never occurred. The cells from the operated newts supplemented with prolactin and estradiol exhibited [Ca(2+)]i responses to sodefrin with a high incidence. Thus, sex- and hormone-dependency as well as species-specificity of the responsiveness of the VN cells to sodefrin was evidenced at the cellular level. Subsequently, possibility of involvement of phospholipase C (PLC)-inositol 1,4,5-trisphosphate (IP3) and/or PLC-diacylglycerol (DAG)-protein kinase C (PKC) pathways in increasing [Ca(2+)]i in VN cells in response to sodefrin was explored using pharmacological approaches. The results indicated that PLC is involved in generating the Ca(2+) signal in all sodefrin-responsive VN cells, whereas IP3 in approximately 50% of the cells and DAG-PKC in the remaining cells. In the latter case, the increase of [Ca(2+)]i was postulated to be induced by the influx of Ca(2+) through the L-type channel. The significance of the finding is discussed.
Subject(s)
Calcium/metabolism , Epithelial Cells/drug effects , Oligopeptides/pharmacology , Salamandridae/physiology , Sex Attractants/pharmacology , Sexual Behavior, Animal/physiology , Vomeronasal Organ/drug effects , Animals , Calcium Signaling , Cell Proliferation , Diglycerides/metabolism , Epithelial Cells/cytology , Epithelial Cells/metabolism , Estradiol/pharmacology , Female , Hypophysectomy , Inositol 1,4,5-Trisphosphate/metabolism , Male , Molecular Imaging , Ovariectomy , Ovary/physiology , Pituitary Gland/physiology , Primary Cell Culture , Prolactin/pharmacology , Protein Kinase C/metabolism , Species Specificity , Vomeronasal Organ/cytology , Vomeronasal Organ/metabolismABSTRACT
The primary intracranial development of olfactory neuroblastomas, outside olfactory epithelium, is rare. We report a case of primary sellar neuroblastoma without any aggressive histopathological features, managed solely surgically without adjuvant therapy, with good outcomes at 3 years. Primary sellar neuroblastomas mostly occur in women in the 4th decade with a context of a non-secreting pituitary tumour. Diagnosis is made on histopathological examination (small cells, fibrillary intercellular background, strong immunoreactivity for neurons markers, negative immunoreactivity for anterior pituitary hormones). Management is based on surgery. Adjuvant treatment is not consensual, largely depends on patient's conditions and aggressive histopathological features.
Subject(s)
Esthesioneuroblastoma, Olfactory/diagnosis , Hypophysectomy , Inappropriate ADH Syndrome/etiology , Sella Turcica , Supratentorial Neoplasms/diagnosis , 3-Iodobenzylguanidine , Adenoma/diagnosis , Adult , Amenorrhea/etiology , Biomarkers, Tumor , Diagnosis, Differential , Esthesioneuroblastoma, Olfactory/chemistry , Esthesioneuroblastoma, Olfactory/complications , Esthesioneuroblastoma, Olfactory/pathology , Esthesioneuroblastoma, Olfactory/surgery , Female , Humans , Hyperprolactinemia/etiology , Iodine Radioisotopes , Magnetic Resonance Imaging , Neoplasm Proteins/analysis , Pituitary Neoplasms/diagnosis , Prognosis , Radiopharmaceuticals , Remission Induction , Supratentorial Neoplasms/chemistry , Supratentorial Neoplasms/complications , Supratentorial Neoplasms/pathology , Supratentorial Neoplasms/surgery , Vision Disorders/etiology , Whole Body ImagingABSTRACT
Both spontaneous hypercortisolism and chronic glucocorticoid treatment are associated with osteoporosis and low circulating concentrations of 1,25-dihydroxy-vitamin D in humans. Pituitary-dependent hypercortisolism (PDH) is a common disorder in dogs, but little is known about the vitamin D status of affected dogs. Pituitary-dependent hypercortisolism in dogs can be treated effectively by hypophysectomy and subsequent hormone supplementation. Because hormone supplementation does not include GH, dogs that have undergone hypophysectomy have low circulating concentrations of GH and IGF-1, which may result in low plasma 1,25-dihydroxy-vitamin D concentrations and consequently increased parathyroid hormone secretion. The aim of this study was to determine whether dogs with PDH need vitamin D supplementation before and/or after hypophysectomy. To this end, we measured plasma concentrations of GH, IGF-1, parathyroid hormone, calcium, phosphate, and vitamin D metabolites in 12 dogs with PDH before and 8 wk after hypophysectomy and in 12 control dogs. Although plasma GH concentrations were lower in dogs with PDH than in control dogs both before and after hypophysectomy, the vitamin D status was similar. In conclusion, there is no need for vitamin D supplementation in dogs with PDH, either before or after hypophysectomy.
Subject(s)
Cushing Syndrome/veterinary , Dog Diseases/blood , Hypophysectomy/veterinary , Vitamin D/analogs & derivatives , Animals , Calcium/blood , Cushing Syndrome/blood , Cushing Syndrome/surgery , Dog Diseases/surgery , Dogs , Female , Growth Hormone/blood , Insulin-Like Growth Factor I/metabolism , Parathyroid Hormone/blood , Phosphates/blood , Statistics, Nonparametric , Vitamin D/bloodSubject(s)
Diabetes Insipidus/etiology , Hypophysectomy/adverse effects , Hypothalamus/metabolism , Inappropriate ADH Syndrome/etiology , Pituitary Gland, Posterior/metabolism , Pituitary Neoplasms/surgery , Vasopressins/metabolism , Child, Preschool , Deamino Arginine Vasopressin/therapeutic use , Dexamethasone/therapeutic use , Diabetes Insipidus/drug therapy , Diabetes Insipidus/physiopathology , Diuretics/therapeutic use , Drug Therapy, Combination , Humans , Hydrocortisone/therapeutic use , Hyponatremia/etiology , Hyponatremia/physiopathology , Hypopituitarism/etiology , Hypothalamus/injuries , Inappropriate ADH Syndrome/drug therapy , Inappropriate ADH Syndrome/physiopathology , Male , Nerve Degeneration , Pituitary Neoplasms/complications , Puberty, Precocious/etiology , Puberty, Precocious/surgery , Secretory RateABSTRACT
OBJECTIVE: Antipituitary (APA) but not antihypothalamus antibodies (AHA) have been investigated in patients with idiopathic hypopituitarism. This study searched for APA and AHA in some of these patients to investigate whether pituitary or hypothalamic autoimmunity could play a role in their pituitary dysfunction. DESIGN: Sixty-six patients with selective idiopathic hypopituitarism were studied: 27 with ACTH deficiency, 20 with GH deficiency and 19 with hypogonadotropic hypogonadism. Twenty patients with hypopituitarism secondary to hypophysectomy and 50 healthy subjects were enrolled as controls. MEASUREMENTS: Antipituitary and AHA were evaluated by indirect immunofluorescence in sera of patients and controls. Positive sera were retested by a four-layer double immunofluorescence to identify the cells targeted by these antibodies. RESULTS: Antipituitary were present at high titre in 4 of 27 patients with ACTH deficiency (14·8%), 4 of 20 with GH deficiency (26%) and 5 of 19 with hypogonadotropic hypogonadism (21%) and targeted, respectively, corticotrophs, somatotrophs and gonadotrophs. AHA were found at high titre only in 5 patients with ACTH deficiency (18·5%), mostly targeting corticotrophin-releasing hormone-secreting cells; none of these 5 patients resulted positive for antipituitary antibodies. Among the controls, only 1 hypophysectomized patient resulted APA positive at low titre. CONCLUSIONS: Our results suggest that in patients with selective idiopathic hypopituitarism, detection of APA or AHA could better characterize an autoimmune process involving the pituitary or hypothalamus, respectively. In particular, detection of antibodies targeting selectively ACTH-secreting or corticotrophin-releasing hormone-secreting cells may differentiate, respectively secondary from tertiary variants of autoimmune hypoadrenalism.
Subject(s)
Autoantibodies/immunology , Hypopituitarism/immunology , Hypothalamus/immunology , Pituitary Gland/immunology , Adrenocorticotropic Hormone/deficiency , Adult , Autoantibodies/blood , Autoimmunity/immunology , Female , Fluorescent Antibody Technique, Indirect/methods , Human Growth Hormone/deficiency , Humans , Hypophysectomy/adverse effects , Hypopituitarism/blood , Hypopituitarism/etiology , Hypothalamus/metabolism , Male , Pituitary Gland/metabolismABSTRACT
OBJECTIVE: To study the effect of growth hormone (GH) combined with Radix Dipsaci on the body growth and the bone mineral content (BMC) of hypophysectomized rats. METHODS: The GH deficiency rats model was established using the hypophysectomized operation through the skull and the throat. Qualified rats were divided into the sham-operation group (n = 15), the negative control group (n = 13), the GH intervention group (n = 13), and the GH combined with Radix Dipsaci group(n = 12). GH (0.25 mg/kg) was subcutaneously injected from the cervical part in the GH intervention group and the GH combined with Radix Dipsaci group at the same time, while equal volume of normal saline was injected to the rest groups. 0.7 mL/100 kg Radix Dipsaci was given by gastrogavage to the GH combined with Radix Dipsaci group at the same time, while equal volume of normal saline was given by gastrogave to the rest groups. The body weight, the tail length, and the body length were measured during the intervention period. Blood was withdrawn after 14-day intervention. The femoral bone and the tibial bone were taken out. The levels of GH, insulin-like growth factor 1 (IGF-1), alkaline phosphatase (ALP), and osteocalcin (OC) were measured. The width of the tibial epiphyseal plate was measured. The bilateral femur bone mineral density (BMD) and BMC were measured using the dual energy X-ray absorptiometry. RESULTS: The body weight, the body length, the length of the femoral bone, the length of the tibial bone, the width of the epiphyseal plate, the levels of the GH, IGF-1, ALP, and OC increased in the GH intervention group and the GH combined with Radix Dipsaci group after 2-week intervention, showing statistical difference when compared with the model group (P < 0.01). But there was no statistical difference in the tail length though it also increased (P > 0.05). There was insignificant difference in the aforesaid indices between the two groups (P > 0.05). Compared with the model group, the BMD of the GH combined with Radix Dipsaci group increased with statistical difference (P < 0.01). Compared with the model group, the BMC of the GH intervention group and the GH combined with Radix Dipsaci group increased with statistical difference (P < 0.01). It was highest in the GH combined with Radix Dipsaci group (P < 0.01). CONCLUSIONS: GH combined with Radix Dipsaci showed unobvious effect on promoting the growth. But it could elevate BMD and BMC, and improve the bone metabolism.
Subject(s)
Bone Development/drug effects , Bone and Bones/metabolism , Drugs, Chinese Herbal/pharmacology , Growth Hormone/pharmacology , Animals , Dipsacaceae/chemistry , Hypophysectomy , Male , Rats , Rats, Sprague-DawleyABSTRACT
<p><b>OBJECTIVE</b>To study the effect of growth hormone (GH) combined with Radix Dipsaci on the body growth and the bone mineral content (BMC) of hypophysectomized rats.</p><p><b>METHODS</b>The GH deficiency rats model was established using the hypophysectomized operation through the skull and the throat. Qualified rats were divided into the sham-operation group (n = 15), the negative control group (n = 13), the GH intervention group (n = 13), and the GH combined with Radix Dipsaci group(n = 12). GH (0.25 mg/kg) was subcutaneously injected from the cervical part in the GH intervention group and the GH combined with Radix Dipsaci group at the same time, while equal volume of normal saline was injected to the rest groups. 0.7 mL/100 kg Radix Dipsaci was given by gastrogavage to the GH combined with Radix Dipsaci group at the same time, while equal volume of normal saline was given by gastrogave to the rest groups. The body weight, the tail length, and the body length were measured during the intervention period. Blood was withdrawn after 14-day intervention. The femoral bone and the tibial bone were taken out. The levels of GH, insulin-like growth factor 1 (IGF-1), alkaline phosphatase (ALP), and osteocalcin (OC) were measured. The width of the tibial epiphyseal plate was measured. The bilateral femur bone mineral density (BMD) and BMC were measured using the dual energy X-ray absorptiometry.</p><p><b>RESULTS</b>The body weight, the body length, the length of the femoral bone, the length of the tibial bone, the width of the epiphyseal plate, the levels of the GH, IGF-1, ALP, and OC increased in the GH intervention group and the GH combined with Radix Dipsaci group after 2-week intervention, showing statistical difference when compared with the model group (P < 0.01). But there was no statistical difference in the tail length though it also increased (P > 0.05). There was insignificant difference in the aforesaid indices between the two groups (P > 0.05). Compared with the model group, the BMD of the GH combined with Radix Dipsaci group increased with statistical difference (P < 0.01). Compared with the model group, the BMC of the GH intervention group and the GH combined with Radix Dipsaci group increased with statistical difference (P < 0.01). It was highest in the GH combined with Radix Dipsaci group (P < 0.01).</p><p><b>CONCLUSIONS</b>GH combined with Radix Dipsaci showed unobvious effect on promoting the growth. But it could elevate BMD and BMC, and improve the bone metabolism.</p>
Subject(s)
Animals , Male , Rats , Bone Development , Bone and Bones , Metabolism , Dipsacaceae , Chemistry , Drugs, Chinese Herbal , Pharmacology , Growth Hormone , Pharmacology , Hypophysectomy , Rats, Sprague-DawleyABSTRACT
OBJECT: Obesity as a consequence of management of pediatric craniopharyngioma is a well-described phenomenon related to the degree of hypothalamic involvement. However, weight change and obesity have not been analyzed in adult patients. Therefore, the purpose of this study was 1) to evaluate the pattern of postoperative weight gain related to preoperative body mass index (BMI), 2) determine if postoperative weight gain is an issue in adult patients, and 3) develop an objective MR imaging grading system to predict risk of postoperative weight gain and obesity in adults treated for craniopharyngioma. METHODS: The authors retrospectively screened 296 patients with known craniopharyngioma for the following inclusion criteria: pathologically confirmed craniopharyngioma, index surgery at the authors' institution, and operative weight and height recorded with at least 3 months of follow-up including body weight measurement. Patients aged 18 years or younger were excluded, yielding 28 cases for analysis. Cases of craniopharyngiomas were compared with age- and sex-matched controls (pituitary adenoma patients) to evaluate the pattern and significance of perioperative weight changes. RESULTS: Mean age was 46 +/- 17 years at surgery, and 64% of the patients were male. Complete resection was achieved in 71% of cases. There was no correlation of preoperative BMI and postoperative weight gain testing in a linear model. Sixty-one percent and 46% of patients had postoperative weight gains greater than 4 and 9%, respectively. Comparing craniopharyngioma patients (cases) to age- and sex-matched controls, the preoperative BMIs were similar (p = 0.93) between cases (mean 28.9 [95% CI 30.9-26.9]) and controls (mean 29.3 [95% CI 31.9-26.7]). However, there was a trend to a greater mean postoperative weight change (percentage) in cases (10.1%) than in controls (5.6%) (p = 0.24). Hypothalamic T2 signal change and irregular contrast enhancement correlated and predicted higher-grade hypothalamic involvement. Furthermore, they can be used to objectively grade hypothalamic involvement as the authors propose. Progressive hypothalamic involvement correlated with larger postoperative weight gains (p = 0.022); however, hypothalamic involvement did not correlate with preoperative BMI (p = 0.5). CONCLUSIONS: Postoperative weight gain in adult patients undergoing surgery for craniopharyngioma is a significant problem and correlates with hypothalamic involvement, as it does in pediatric patients. Finally, objective MR imaging criteria can be used to predict risk of postoperative weight gain and aid in grading of hypothalamic involvement.
Subject(s)
Craniopharyngioma/surgery , Magnetic Resonance Imaging/statistics & numerical data , Obesity/diagnosis , Pituitary Neoplasms/surgery , Postoperative Complications/diagnosis , Adolescent , Adult , Age Factors , Body Mass Index , Craniopharyngioma/pathology , Female , Follow-Up Studies , Humans , Hypophysectomy/methods , Hypothalamus/pathology , Hypothalamus/surgery , Male , Pituitary Neoplasms/pathology , Preoperative Care , Retrospective Studies , Risk Factors , Weight GainABSTRACT
BACKGROUND: To clarify the mechanism of stress-induced modification of allergic diseases, we studied the effect of restraint stress on plasma levels of cytokines and the symptoms of pollinosis in mice. METHODS: The effects of restraint stress and the role of the hypothalamo-pituitary-adrenal axis (HPA-axis) in the development of pollen antigen-induced pollinosis were studied in control, hypophysectomized, adrenalectomized or ACTH-administered mice. Twenty days after sensitization, animals were subjected to mild restraint stress for 3 hours, and plasma levels of IFN-gamma, IL-10, and IgE were measured. We analyzed the incidence of sneezing and nasal rubbing in the sensitized animals. RESULTS: Plasma levels of IL-10 and IgE increased in the sensitized animals with a concomitant increase in the incidence of sneezing and nasal rubbing. The increases in plasma IgE, IL-10 and the incidence of sneezing and nasal rubbing were suppressed by restraint stress. Adrenalectomy increased IFN-gamma, inhibited the increase in plasma IL-10 and IgE, and suppressed the incidence of sneezing. In contrast, hypophysectomy increased plasma levels of IL-10, IFN-gamma, and IgE and the incidence of sneezing. Intraperitoneal administration of ACTH decreased IL-10 in plasma but increased IFN-gamma and suppressed the incidence of nasal rubbing. CONCLUSIONS: The present findings show that the HPA-axis and ACTH play important roles in the regulation of plasma cytokines and IgE thereby modulating symptoms of pollinosis. The results also suggest that a mild restraint stress suppresses the increase in Th2-dependent cytokines and IgE to reduce the symptoms of pollinosis.
Subject(s)
Hypothalamo-Hypophyseal System/immunology , Pituitary-Adrenal System/immunology , Rhinitis, Allergic, Seasonal/immunology , Adrenalectomy , Adrenocorticotropic Hormone/administration & dosage , Animals , Antigens, Plant/immunology , Hypophysectomy , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/surgery , Immunoglobulin E/blood , Interferon-gamma/blood , Interleukin-10/blood , Male , Mice , Mice, Inbred Strains , Pituitary-Adrenal System/drug effects , Pituitary-Adrenal System/surgery , Pollen/adverse effects , Restraint, Physical , Rhinitis , Rhinitis, Allergic, Seasonal/blood , Rhinitis, Allergic, Seasonal/physiopathology , Rhinitis, Allergic, Seasonal/surgery , Stress, Physiological/immunologyABSTRACT
We report an episode of transient, severe hypertension occurring within 2 minutes of injection of 1% lidocaine with 1:100,000 U of epinephrine in a patient taking midodrine for orthostatic hypotension. We hypothesize that the patient's autonomic nervous system was dangerously susceptible to the effect of local anesthetic when combined with the vasoactive systemic effect of midodrine. Surgeons should minimize the use of vasoconstrictors in patients treated with midodrine to avoid hypertensive complications.